HAEK Haemato AG

DGAP-News: HAEMATO AG: Annual General Meeting postponement

DGAP-News: HAEMATO AG / Key word(s): AGM/EGM
HAEMATO AG: Annual General Meeting postponement

27.05.2020 / 08:42
The issuer is solely responsible for the content of this announcement.


HAEMATO AG Corporate News:
Due to the present imponderables HAEMATO AG will reschedule the Annual General Meeting originally intended on July 8, 2020 to a later date.


Due to the current uncertainties around the COVID-19 pandemic the Executive Board and the Supervisory Board of HAEMATO AG, Berlin (ISIN: DE0006190705), have decided to postpone the Annual General Meeting originally scheduled on July 8, 2020 to a later date this year. We consider the health of our shareholders, staff members and relevant service providers to be of the utmost priority.

The new date of the Annual General Meeting will be disclosed in due course at a later time.

As one of the leading providers of specialty pharmaceuticals, the HAEMATO Group benefits from competition in the primary healthcare market. The specialization in medicines for the treatment of chronic diseases and for individual therapies leads us to expect a potential for growth in the future due to demographic development.

About HAEMATO:

HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of high-priced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases.

HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures on the HAEMATO AG share:
Subscribed capital: EUR 22,867,154
Listed class of shares: bearer ordinary shares
ISIN: DE000619070
WKN: 619070
Stock exchange code: HAE




Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70


27.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany
Phone: +49 (0)30 897 30 86 70
Fax: +49 (0)30 897 30 86 79
E-mail:
Internet:
ISIN: DE0006190705
WKN: 619070
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1056103

 
End of News DGAP News Service

1056103  27.05.2020 

fncls.ssp?fn=show_t_gif&application_id=1056103&application_name=news&site_id=research_pool
EN
27/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Haemato AG

Cosmin Filker
  • Cosmin Filker

Investment im Fokus - Haemato AG - 04.08.23

- Herstellerzwangsrabatte belasten „Specialty Pharma“-Segment - Lifestyle & Aesthetics“-Segment sollte in 2023 wachsen - hohe Potenziale mit Botox-Einführung vorhanden - Steigerung der Rentabilität erwartet Erwartungsgemäß weist die HAEMATO AG für das abgelaufene Geschäftsjahr 2022 einen Umsatzrückgang auf 248,14 Mio. € (VJ: 285,04 Mio. €) aus und liegt damit knapp unterhalb der zuvor erwarteten Umsatzbandbreite von 250 bis 280 Mio. €. Der Umsatzrückgang ist dabei auf den Wegfall des Vertriebs ...

Cosmin Filker ... (+2)
  • Cosmin Filker
  • Marcel Goldmann

Rresearch Comment englisch - Haemato AG - 17.04.2023

HAEMATO AG is a listed company with a focus on the specialty pharma and lifestyle pharma sectors. Their business activities are concentrated on growth markets for off-patent and patent-protected drugs. Their main focus is on the therapeutic areas of oncology, HIV/AIDS, neurology, cardiovascular and other chronic diseases. In the fast-growing market of aesthetic medicine, HAEMATO AG focuses on the largest market for private payers. The need for affordable medicines that are delivered at the highe...

Cosmin Filker ... (+2)
  • Cosmin Filker
  • Marcel Goldmann

Research Comment deutsche - Haemato AG - 17.04.2023

Die HAEMATO AG ist ein börsennotiertes Unternehmen mit Fokus auf den Bereichen Specialty-Pharma und Lifestyle-Pharma. Die Geschäftsaktivitäten konzentrieren sich auf Wachstumsmärkte patentfreier und patentgeschützter Arzneimittel. Schwerpunkte bilden die Therapiebereiche Onkologie, HIV/AIDS, Neurologie, Herz-Kreislauf- und andere chronische Erkrankungen. Im schnell wachsenden Markt der ästhetischen Medizin fokussiert sich die HAEMATO AG auf den größten Markt für Privatzahler. Der Bedarf an preis...

Cosmin Filker ... (+2)
  • Cosmin Filker
  • Marcel Goldmann

Research Note englisch - Haemato AG - 13.09.22

HAEMATO AG is a listed company with a focus on the specialty pharma and lifestyle pharma sectors. Their business activities are concentrated on growth markets for off-patent and patent-protected drugs. Their main focus is on the therapeutic areas of oncology, HIV/AIDS, neurology, cardiovascular and other chronic diseases. In the fast-growing market of aesthetic medicine, HAEMATO AG focuses on the largest market for private payers. The need for affordable medicines that are delivered at the highe...

Cosmin Filker ... (+2)
  • Cosmin Filker
  • Marcel Goldmann

Research Note - Haemato AG - 13.09.22

Die HAEMATO AG ist ein börsennotiertes Unternehmen mit Fokus auf den Bereichen Specialty-Pharma und Lifestyle-Pharma. Die Geschäftsaktivitäten konzentrieren sich auf Wachstumsmärkte patentfreier und patentgeschützter Arzneimittel. Schwerpunkte bilden die Therapiebereiche Onkologie, HIV/AIDS, Neurologie, Herz-Kreislauf- und andere chronische Erkrankungen. Im schnell wachsenden Markt der ästhetischen Medizin fokussiert sich die HAEMATO AG auf den größten Markt für Privatzahler. Der Bedarf an preis...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch